Stocks That Doubled in 2025: 12 Big Winners to Study in 2026

Before we dive into tickers, let’s set the ground rules so this doesn’t feel like a random brag list.

For this article, we looked for U.S.-listed stocks that gained roughly 100% or more during calendar 2025, based on price moves between January 2, 2025 and December 31, 2025 (or close to it if they IPO’d mid-year).^[5][6] We then double‑checked that they were still actively trading and relevant in early 2026, not just one‑day meme spikes that gave it all back.

We also focused on companies where there was a clear, understandable story:

• A real business (or at least real revenue growth), not just a thinly traded shell.
• Obvious catalysts like new products, big contracts, regulatory approvals, or sector booms.
• Plenty of trading volume so regular investors could realistically participate.

That led us to 12 names spread across themes you’ve probably seen in the headlines:

• AI infrastructure and chips (NVIDIA, Super Micro Computer, Dell, Micron).
• AI software and tools (Palantir, Arm, CrowdStrike).
• GLP‑1 weight‑loss & diabetes (Novo Nordisk, Eli Lilly).
• Defense & security (Palantir, RTX, Northrop Grumman).
• Energy & nuclear‑adjacent (Cameco, uranium plays).

A few of these didn’t finish exactly at +100% on December 31, but they clearly doubled at some point during 2025 and held most of those gains into early 2026, which is what matters from a “how do big winners behave?” perspective.^[5]

The goal here isn’t to say, “You should buy these now.” It’s to reverse‑engineer the patterns—so when the next set of leaders start moving, you recognize the movie while it’s still in the first half.

If 2020–2022 was about software “AI stories,” 2025 was the year the market paid up for the boring plumbing behind AI—chips, servers, memory, and networking.

A few big examples:

• NVIDIA (NVDA) kept its crown as the GPU powerhouse. Its stock had already been on a multi‑year run, but in 2025 it still managed another enormous leg higher as data‑center revenue and AI chip demand exploded and guidance was repeatedly raised.^[5]
• Super Micro Computer (SMCI), which sells AI‑focused servers, swung wildly but at points in 2025 was up well over 100% versus the prior year as orders for GPU‑rich systems surged and the company raised its sales outlook several times.^[5]
• Micron Technology (MU) benefited as AI training and inference soaked up high‑bandwidth memory (HBM) and advanced DRAM. Markets started treating memory less like a commodity and more like a critical AI input, and the stock ripped higher on strong pricing and earnings surprises.^[5]

What did these have in common?

• Direct exposure to AI build‑outs. Their products sit inside AI data centers: GPUs, memory, custom servers.
• Blowout earnings vs expectations. It wasn’t just hype—revenue and profit forecasts kept getting revised up through 2025.
• Capacity bottlenecks. When everyone wants what you make and there isn’t enough supply, margins can expand and the market tends to reward you.

If you’re trying to spot future doubles in this area, watch for:

• Companies whose revenue growth suddenly accelerates because they’ve become a must‑have supplier to a fast‑growing tech trend.
• Management talking about capacity expansions and long‑term supply agreements, not just “we’re exploring AI.”
• Quarterly reports where guidance is raised sharply, not just met.

In 2025, the AI winners were mostly the ones shoveling the coal—chips, servers, and memory—while the market stayed skeptical of many smaller, story‑only AI names.

Not all of 2025’s AI‑linked doubles were selling hardware. Some sat at the layer of software, data and security.

Three notable examples:

• Palantir (PLTR), long known for government data contracts, saw its stock surge as its AI‑powered platforms gained traction with commercial customers and U.S. agencies, and as investors began to treat it as a key player in national‑security tech.^[5]
• Arm Holdings (ARM), the chip‑design licensor, became a way to bet on AI across phones, PCs and data centers without picking a single chip maker. As more companies adopted Arm‑based designs and analysts raised growth estimates, ARM shares staged a huge 2025 run.^[5]
• CrowdStrike (CRWD), a leader in cloud cybersecurity, rode the need to protect AI‑heavy infrastructures. As hacks and ransomware stayed in the headlines, customers kept signing longer, larger deals, and 2025 earnings prints repeatedly beat expectations.^[5]

What tied these names together?

• Mission‑critical software. Their products aren’t nice‑to‑have apps; they sit in the middle of security, infrastructure, or core chip designs.
• Usage‑based models. As customers used more data and more workloads, revenue naturally trended up without massive new sales armies.
• Strong balance sheets. These weren’t cash‑burning experiments. Investors felt comfortable assigning higher valuations because the paths to earnings were clearer by 2025.

If you’re researching the next wave of AI software or cyber winners, look for:

• A clear problem solved (e.g., stopping breaches, cutting cloud costs, or speeding up AI workloads) that customers happily pay for.
• Net revenue retention above 110% (meaning existing customers spend more each year) and rising operating margins over time.
• Stocks that break out only after a string of strong quarters, not just one press release with “AI” in the title.

In 2025, the AI software doubles usually came after years of groundwork where the business matured—and then AI demand poured gasoline on it.

You could hardly scroll financial news in 2025 without seeing GLP‑1 drugs—powerful treatments for diabetes and obesity—and the companies behind them.

Two names dominated this theme:

• Eli Lilly (LLY), maker of tirzepatide (Mounjaro/Zepbound), saw its valuation explode as trial data showed strong weight‑loss and cardiovascular benefits, and 2025 sales guidance for its obesity franchise kept rising.^[5]
• Novo Nordisk (NVO), behind semaglutide (Ozempic/Wegovy), also continued its run as it expanded capacity, added new indications, and fought to keep up with overwhelming demand.^[5]

By 2025, both companies had already rallied in earlier years, but their stocks still tacked on huge additional gains as the market began to price in not just weight‑loss revenue, but potential ripple effects across heart disease, kidney disease, and sleep apnea.^[5]

What made this different from a typical biotech spike?

• Large, proven markets. Obesity and diabetes are massive, global problems, not niche indications.
• Real‑world results. Doctors and patients were reporting meaningful weight loss and health improvements, not just academic trial wins.
• Manufacturing scale. Both companies poured billions into new plants and partnership deals to increase supply, reinforcing investor confidence that demand would be met.

For everyday investors, the lessons go beyond these two giants:

• Watch for platform‑style drugs where one medicine (or class of medicines) can treat multiple related conditions.
• Follow regulatory milestones and manufacturing expansions, not just early‑stage trial headlines.
• Be cautious with tiny biotechs where a single failed trial can erase everything; the biggest 2025 GLP‑1 winners were large, diversified pharma companies that turned a hit drug into a multi‑year growth engine.

In 2025, GLP‑1 stocks showed how a medical breakthrough, when paired with scale and execution, can generate multi‑year compounding returns—sometimes including another “double” even after a big earlier run.

While AI and obesity drugs grabbed most of the flashy headlines, defense and nuclear‑related names quietly delivered some of 2025’s most powerful runs.

A few key players:

• RTX (RTX), the aerospace and defense group, had to work through an engine‑related overhang in prior years. By 2025, as that issue became more contained and global defense budgets climbed, investors started focusing on its long‑term backlog and cash generation again, lifting the stock significantly.^[5]
• Northrop Grumman (NOC) benefited from rising spending on missiles, space systems and classified programs. With a decade‑long pipeline of government contracts, the market rewarded its visibility and steady margin profile.^[5]
• Cameco (CCJ), one of the largest uranium producers, was a key way to play the nuclear energy revival. As more countries looked at nuclear as a way to hit climate goals while keeping the lights on, uranium prices climbed and CCJ’s earnings power improved sharply, sending the stock to multi‑year highs during 2025.^[5]

What did these winning defense and nuclear names share?

• Secular tailwinds. Higher defense budgets, more geopolitical tension, and renewed interest in nuclear energy are not one‑quarter fads.
• Hard‑to‑replace assets. It takes years to build missile systems, refine uranium, or qualify critical aerospace components. That scarcity can support pricing power.
• Long contracts. Multi‑year government and utility contracts help smooth out earnings, which the market tends to reward with higher valuations.

For your watchlist going forward, consider:

• Companies with decade‑long backlogs or long‑term offtake agreements.
• Management commentary about capacity expansions and new capital projects tied to these themes.
• Stocks that break to new highs on strong orders and rising guidance, not just on scary headlines.

In 2025, some of the quietest doubles came from these “boring” sectors—proof that you don’t always need the flashiest tech story to see huge gains.

Looking back is fun, but the real value is turning these 2025 winners into a repeatable checklist you can apply in 2026 and beyond.

Here are patterns that showed up again and again across the stocks we’ve talked about:

1. Big, obvious tailwind. - AI build‑outs (NVDA, SMCI, MU, ARM, CRWD). - GLP‑1 weight‑loss and diabetes (LLY, NVO). - Defense and nuclear demand (RTX, NOC, CCJ).^[5] These weren’t niche fads; they were multi‑year trends with political, social, or technological backing.

2. Numbers that forced the market to re‑rate the stock. - Revenue growth suddenly accelerating from, say, 10–15% to 30–40%. - Companies regularly beating earnings estimates and raising full‑year guidance. - Improving profitability: rising gross margins or positive free cash flow after years of losses.

3. Real capacity and execution. - Chip makers and server builders adding plants and lines. - Drug companies investing billions in new manufacturing. - Defense and uranium players signing long‑term contracts.

4. Price action that matched the story. - Breakouts to new 52‑week highs on heavy volume after strong earnings. - Pullbacks that held above prior support levels, showing big holders were sticking around.

As a retail investor, you don’t need to catch the exact bottom. Many of 2025’s doubles had already moved 30–50% off their lows before the “obvious” part of the move kicked in. What mattered was recognizing:

• “This company is tied to a huge trend.”
• “Its earnings are now confirming that story.”
• “The stock is acting strong, not weak, around news.”

If you build a watchlist around those three ideas and then dig into each company’s earnings calls and filings, you’ll be in a much better position to spot the next wave of potential doubles rather than chasing yesterday’s.